Diminished GATA4 protein levels contribute to hyperglycemia-induced cardiomyocyte injury

Satoru Kobayashi1, Kai Mao, Hanqiao Zheng

  • 1Cardiovascular Research Institute, Sanford Research, University of South Dakota Sanford School of Medicine, Sioux Falls, SD 57105, USA.

Insights

High glucose reduces cardiac GATA4 protein by increasing its degradation via CHIP, a mechanism contributing to diabetic heart failure. Enhancing GATA4 protects against this damage.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Diabetology

Background:

  • Hyperglycemia is a key risk factor for diabetic heart failure.
  • Mechanisms of hyperglycemia-induced cardiac damage are not fully understood.
  • GATA4 transcription factor is crucial for heart health and reduced by stress.

Purpose of the Study:

  • Investigate if hyperglycemia impacts GATA4 expression in cardiomyocytes.
  • Determine if boosting GATA4 signaling can prevent hyperglycemia-induced cardiomyocyte injury.

Main Methods:

  • Cultured rat cardiomyocytes exposed to high glucose (HG) or normal glucose (NG).
  • Assessed GATA4 protein and mRNA levels, proteasome activity, and CHIP expression.
  • Utilized proteasome inhibitors, CHIP overexpression/knockdown, and GATA4 overexpression.
  • Examined GATA4 levels in hearts of diabetic mouse models (streptozotocin and db/db).

Main Results:

  • High glucose significantly reduced GATA4 protein levels in cardiomyocytes, but not mRNA.
  • GATA4 reduction was linked to increased CHIP (E3 ligase) and proteasomal degradation.
  • Overexpression of GATA4 protected cardiomyocytes from high glucose-induced death.
  • Diabetic mice showed decreased GATA4 and increased CHIP mRNA in heart tissue.

Conclusions:

  • Hyperglycemia induces GATA4 protein degradation through the CHIP-ubiquitin-proteasome pathway.
  • This GATA4 downregulation contributes to hyperglycemic cardiotoxicity.
  • Targeting GATA4 degradation may offer a therapeutic strategy for diabetic heart failure.

Related Concept Videos

Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes: